7 Most Promising Gene Editing Stocks According to Analysts

5. Natera, Inc. (NASDAQ:NTRA) 

Price Target Upside: 11.24%

Natera, Inc. (NASDAQ:NTRA) stands sixth on our list among the most promising stocks. 

TheFly reported on December  15 that J.P. Morgan raised its price target on NTRA from $250 to $260 while maintaining an Overweight rating, reflecting confidence in the company’s growth prospects driven by strong operational momentum and rapid adoption of its Signatera molecular residual disease (MRD) test.

Around the same time, Barclays maintained its Overweight rating with a $270 price target, and Jefferies raised its target to $275, underscoring broad analyst optimism about Signatera’s role in oncology diagnostics and recurring revenue potential.

The bullish sentiment is supported by recent clinical and scientific validation of Signatera. On December 18,  Natera, Inc. (NASDAQ:NTRA) announced the publication of Phase III CALGB (Alliance)/SWOG 80702 data in JAMA Oncology showing that Signatera‑positive colorectal cancer patients had significantly improved outcomes when treated with celecoxib plus chemotherapy versus chemotherapy alone, reinforcing the test’s prognostic utility in solid tumors.

Further strengthening confidence, NTRA completed its acquisition of Foresight Diagnostics on December 5,  integrating Foresight’s ultrasensitive phased variant MRD technology into the business’s portfolio to enhance ctDNA detection capabilities, especially in lymphoma and other solid tumors. The deal was valued at $275 million upfront with up to $175 million in milestone payments, positioning NTRA to extend its MRD leadership.

Natera, Inc. (NASDAQ:NTRA) is a leader in clinical genetic testing and molecular diagnostics that uses advanced DNA analysis to inform patient care. It enables precision health decisions through interpreting genetic information.